The 17th Taizhou Pharmaceutical Expo will be held at the China Medical City Convention and Exhibition Center on November 27–28, 2026. As a data infrastructure provider for the upstream segment of the AI virtual cell industry, Liman Bio will be exhibiting at the event. Booth G51, Hall E1-2 , we sincerely invite you to visit and exchange ideas.

The company focuses on applying high-throughput cell-editing technologies and automated systems to generate arrayed perturbation libraries and multimodal time-series datasets, offering wet-lab solutions that span from perturbed samples and perturbation data to model result validation, thereby accelerating the emergence of a data flywheel in the AI-driven virtual cell space.

Time: November 27–28, 2026

Location: China Medical City Convention and Exhibition Center

Liman Bio Booth : Hall E1-2, G51

I. Conference Overview

The current edition of the Medical Expo is planned to cover 30,000 square meters, focusing on the entire pharmaceutical and greater health industry chain, with plans for... 1 match Opening ceremony, Seven Greats Core exhibition area, with supporting facilities of approximately 20+ Diverse thematic activities, building a « 1+7+N The exhibition will feature nearly 300 exhibitors engaging in exchanges, while leading companies, industry pioneers, and experts and scholars from both domestic and international biopharmaceutical and greater health industries will gather in China Pharmaceutical City to discuss the future of industry development.

Covering seven core exhibition areas:

1) Greater Health Lifestyle Exhibition Area

2) Comprehensive Industrial Services Exhibition Area

3) Frontier Biotechnology and Innovative Diagnosis & Treatment Exhibition Area

4) CRO/CDMO Industrialization Services Exhibition Area

5) Integrated Zone for Key Achievements and Interactive Experiences

6) R&D Equipment and Biological Consumables Exhibition Area

7) Innovative Medical Devices and Services Exhibition Area

20+ diverse thematic matchmaking and exchange events:

Topic 1: Global eCTD Submission Practices and Future Prospects

Topic 2: Innovation and Development of Cell Growth Factors and Their Antibody Drugs

Topic 3: Biopharmaceuticals Going Global: Overseas Market Expansion and Compliance

Topic 4 Advanced Analytical Techniques and Quality Evaluation of Biopharmaceuticals

Topic 5: Covering the Entire Lifecycle of Microorganisms to Safeguard Quality and Safety Across Multiple Sectors Including Pharmaceuticals, Medical Devices, and Food

Topic 6: Development of Immunotherapeutic and Anti-Tumor Biologics

Topic 7: New Methodologies for New Drug Evaluation

Topic 8: New Discoveries in Antibodies and In Vivo CAR-T

Topic 9: Digital-Intelligent Healthcare Integration, Pioneering the Future: Innovative Development of AI in Medicine

Topic 10: AI Virtual Cells and Multimodal Data Acquisition

Topic 11: Health, Longevity, and Anti-Aging

Topic 12: Beyond Traditional ADCs: From Chinese XDC Innovation to Global Therapeutic Value

Topic 13: Innovation in Peptide Drugs

Topic 14: Cutting-Edge Technologies in Special Medical Foods, Clinical Nutrition Practices, and Industrial Ecosystem Development

Topic 15 Synthetic Biology and Pharmaceutical Innovation

Topic 16: From Involution to Incremental Growth: Reconstructing the Value Trajectory of Pet Pharmaceuticals

Topic 17: Integrating AI into the Decision-Making Pipeline of Drug Discovery

Special Topic 18 in vivo CAR-T

Topic 19: Innovations in Brain-Computer Interfaces and Neuromodulation Devices

Topic 20: Medico-Engineering Integration: From Clinical Pain Points to the Translation and Commercialization of Innovative Medical Device Innovations

More events are being confirmed...

II. Key Highlights of LIMAN’s Participation: One Booth, One Roundtable

Key Point 1: Hall E1-2, Booth G51

As a technology service provider specializing in cellular and genetic editing, Leman Bio will be exhibiting at Booth G51 in Hall E1-2, offering in vitro cell-editing products and custom services for new drug discovery and basic research. These offerings cover high-throughput gene knockout (KO), gene knockdown (KD/CRISPRi), gene activation and overexpression (CRISPRa/OE), in situ or site-specific knock-in (KI), point mutations, reporter cells, and HiBiT models. Together, these capabilities can deliver the diverse, controllable functions required by AIVC:

• KO / CRISPRi: Observe the changes in the state of the target after its deletion or reduced expression;
• CRISPRa / OE: Testing whether expression enhancement can drive, compensate for, or reverse a given state;
• KI / Point Mutations: Investigating the effects of specific allelic variants, tags, or loci in their endogenous context;
• HiBiT / Reporting Cell: Converts protein stability, degradation, or signaling changes into quantitative readouts;
• Multiple guides and orthogonal strategies: help distinguish true target effects from off-target responses.

For details, please see “AIVC Special Feature | AIVC Enters the Data Competition: Who Can Provide Verifiable Cell Perturbation Data?”

Notably, as AI-driven drug discovery rapidly advances, the value of high-throughput cell editing is expanding—from “Delivering a single cell” extends to “producing perturbation samples and data that are trainable and verifiable.” . We welcome those who are developing AI-powered virtual cell platforms, single-cell foundational models, or drug perturbation prediction platforms to visit our booth for in-depth discussions.

Key Point Two: Roundtable Discussion on the “AI Virtual Cells and Multimodal Data Acquisition” Topic

November 27, 09:00-12:00 The special event “AI Virtual Cells and Multimodal Data Acquisition” of this year’s Medical Expo will be held during the exhibition.

The AI Virtual Cell (AIVC) has been hailed by the journal Cell as the next-generation paradigm for cell research. However, a pressing challenge remains: industry still lacks the data needed to make these models “trustworthy.” Single-cell transcriptomics, proteomics, spatiotemporal omics, organ-on-a-chip systems, and genetic perturbations—all generate data—but these modalities remain siloed, with causal signals lost amid noise from correlations. The final hurdle in moving virtual cells from “prediction” to “programmability” lies in the acquisition, alignment, and validation of multi-modal data.

This special feature takes Liman Bio, Teams such as Luomi Intelligence, Lianchuan Bio, Yaosu Technology, and WuJie Evolution—each contributing to building a data foundation from different angles—have been brought together. Their work spans areas including high-throughput cell editing and verifiable perturbation datasets, open-source RNA perturbation datasets, organ-on-a-chip models, proteomics-based virtual cell models, the RSI recursive autonomous research platform, and spatiotemporal multi-omics studies on tumor drug resistance. At the roundtable discussion beginning at 11:10, participants will explore “The Next Frontier of AI Virtual Cells: From Model Prediction to Drug Discovery.”

 

Agenda for the Special Session

09:00-09:10 Opening Remarks

09:10-09:30 AI4S Traceable Closed Loop: RSI Recursive Self-Evolution Driving TechBio 3.0

Wu Hao: Founder & CEO of Luomi Intelligence

09:30-09:50 How to Obtain High-Quality Gene-Perturbation-Based Virtual Cell RNA Data

Shen Lizhe: Head of AIVC at Lianchuan Bio

09:50-10:10 AI for RSD: A Next-Generation Autonomous Research Platform Driven by Recursive Scientific Discovery

Yang Qianyi: Head of Borderless Evolution Products

10:10–10:30 From Organ-on-a-Chip to Virtual Cell: Building a Humanized Perturbation Data Factory to Strengthen the Data Foundation of AIVC

Ye Sen: Head of Scientific Affairs at Shanghai Yaosu Technology

10:30-10:50 Ultra-large-scale experimental data acquisition based on cellular programming

Guo Haotian: Founder and CEO of Ailurus Bio

10:50-11:10 Research on Tumor Drug Resistance from a Spatiotemporal Perspective

Wang Nan: Chief Scientific Officer, Hangzhou Guangke Ande Biotechnology Co., Ltd.

11:10-12:00 Roundtable Discussion: The Next Frontier of AI-Powered Virtual Cells: From Model-Based Prediction to Drug Discovery

Wu Hao: Founder & CEO of Luomi Intelligence

Ye Sen: Head of Scientific Affairs at Shanghai Yaosu Technology

Cheng Yongbo: Founder & CEO of Liman Bio

Yang Qianyi: Head of Borderless Evolution Products

Liu Huan: Director of Strategic Business Development at Baitu Bioscience

III. Conclusion

Currently, the Liman team is collaborating with AIVC model companies, AI-driven pharmaceutical firms, innovative drug developers, and research institutions to build a closed-loop experimental data pipeline encompassing “model prediction—standardized perturbations—multimodal readout—independent validation—retraining.”

If you are building AI-powered virtual cells, single-cell foundational models, or drug perturbation prediction platforms, and need to establish high-throughput KO, CRISPRi/a, OE, KI, HiBiT, or multimodal validation datasets around specific targets, pathways, or cellular contexts, we invite you to visit Booth G51 in Halls E1–E2 on November 27–28 to discuss joint datasets, model blind-test sets, and active learning experimental protocols with us.

November 27–28, Taizhou—see you there!